News

Dundalk, Ireland, January 6, 2025 – WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), today announced that it has entered into a definitive agreement with MSD International GmbH (MSD), under which MSD will acquire WuXi Vaccines’ facility in Dundalk, Ireland for approximately USD 500 million pending adjustments.

In 2019, WuXi Vaccines announced the investment in building a dedicated vaccine manufacturing facility for MSD, including drug substance manufacturing (DS), drug product manufacturing (DP), manufacturing science and technology labs (MS&T), and Quality Control labs (QC). Since 2022, the state-of-the-art facility has been focused on technology transfer activities to manufacture high-quality vaccine for the global market. Its QC Potency Lab, recognized for its innovative design, was awarded the “Large Project of the Year” at the 2020 Ireland Pharma Industry Awards and received the HPRA GMP license in July 2022. The main production facility (including DS, DP, the main QC lab, warehouse, and utilities) is in due course for HPRA GMP certification in 2025.

“The world-class facility is designed and built to support MSD’s business growth strategy, and this transaction highlights our capability of building and operating the state-of-the-art complex vaccine manufacturing facilities meeting stringent standards of global vaccine leaders. This deal will enable our partner MSD to better integrate vaccine production into their global manufacturing network. For WuXi Vaccines, the deal enhances our asset efficiencies and margins, allowing us to focus on CDMO services from our sites in Suzhou China. The cash proceeds from the transaction can be utilized to elevate our global network, enabling us to better serve our global customers and benefit patients worldwide. Additionally, the proceeds can be used for share buybacks”, Dr. Chris Chen, Chairman of WuXi Vaccines, stated, “We thank our WuXi Vaccines Ireland colleagues for all of their contributions. WuXi Vaccines will continue our global operations to support and enable our client’s success in bringing innovative vaccines to populations worldwide.”

The transaction is expected to be concluded in the first half of 2025, subject to the satisfaction of customary closing conditions. This transaction has no impact on biologics manufacturing facilities in Ireland and vaccine facilities in Suzhou.

About WuXi Vaccines

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine and preventive antibody’s development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners’ vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., recombinant protein, viral, viral vectored, VLP, OMV, nucleic acid, conjugated vaccines). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (cell culture, viral, microbial, polysaccharide and protein conjugation), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine development to large-scale commercial production and distribution. The company can enable global clients to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health.

For more information about WuXi Vaccines, please visit: https://wuxivaccines.com

———————————————————————————————————————

药明海德就其爱尔兰疫苗工厂与默沙东达成协议

爱尔兰敦多克，2025年1月6日，药明海德（WuXi Vaccines）为药明生物全资子公司，专注于疫苗合同定制研发和生产（CDMO）业务 。公司今日宣布就其爱尔兰疫苗工厂与默沙东（MSD International GmbH）达成协议。根据协议，默沙东将收购药明海德在爱尔兰的疫苗工厂，总交易金额约为5亿美元。

2019年，药明海德宣布在爱尔兰为默沙东投资建设专属疫苗工厂，包括原液生产（DS），制剂生产（DP），生产科技实验室（MS&T）以及质量控制实验室（QC）。这一现代化工厂从2022年开始专注于技术转移，以便为全球市场生产高质量的疫苗。质量控制效价实验室凭借其创新设计，在2020年爱尔兰医药行业评奖中荣获“年度大项目奖”，并于2022年7月获爱尔兰健康产品监管局(HPRA) GMP认证。该厂的主要生产设施（包含制剂、原液生产设施、质量控制主实验室、仓库及公用设施）将于2025年进行爱尔兰健康产品监管局 GMP认证。

“该工厂采用了世界一流的设计和建造，全面支持我们的合作伙伴默沙东的业务增长战略。本次交易充分证明，我们有能力按照全球疫苗巨头的最高国际标准，建设和运营世界领先的复杂疫苗生产设施。通过本次交易，默沙东能够将疫苗生产更好地融入其全球生产网络。药明海德也能进一步提升其资产效率和利润，聚焦中国苏州基地为客户提供CDMO服务。本次交易的收益可用于进一步提升我们的全球网络，让我们更好地服务全球客户，惠及全球病患，也可用于公司股票回购。”药明海德董事长陈智胜博士表示，“感谢药明海德爱尔兰同事的付出和奉献，药明海德将持续全球运营，支持和赋能我们的客户成功，生产更多创新疫苗，守护人类健康。”

本次交易预计将在2025年上半年满足惯例交割条件完成。本次交易对爱尔兰的生物药工厂和苏州疫苗工厂均无任何影响。

关于药明海德

药明海德（WuXi Vaccines）为药明生物全资子公司，专注于疫苗合同定制研发和生产（CDMO）业务 。公司通过一体化能力和技术平台，赋能合作伙伴加速疫苗与预防性抗体研发和商业化进程。无论是预防性单抗、重组蛋白疫苗、病毒类疫苗、病毒载体疫苗、病毒样颗粒（VLP）疫苗、外膜囊泡（OMV）疫苗、核酸疫苗还是结合疫苗，公司都能够通过精深的技术专长、广泛的监管知识、一流的质量体系、先进的CMC开发能力、多元化的技术平台（如哺乳动物细胞、微生物、病毒、蛋白结合技术）以及充沛的GMP产能，为合作伙伴提供从开发到大规模商业化生产的端到端服务，在全球市场交付疫苗和预防性抗体产品，为公众健康保驾护航。

如需了解更多信息，请访问https://wuxivaccines.com